HATALOVA, Antónia, Jiri SCHWARZ, Mirjana GOTIC, Miroslav PENKA, Mikulas HRUBISKO, Rajko KUSEC, Miklos EGYED, Martin GRIESSHAMMER, Maria PODOLAK-DAWIDZIAK, Andrzej HELLMANN, Sergiy KLYMENKO, Emilia NICULESCU-MIZII, Petro E. PETRIDES, Sebastian GROSICKI, Matjaz SEVER, Nathan CANTONI, Juergen THIELE, Dominik WOLF and Heinz GISSLINGER. Recommendations for the diagnosis and treatment of patients with polycythaemia vera. European Journal of Haematology. Hoboken: Wiley-Blackwell, 2018, vol. 101, No 5, p. 654-664. ISSN 0902-4441. Available from: https://dx.doi.org/10.1111/ejh.13156.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Recommendations for the diagnosis and treatment of patients with polycythaemia vera
Authors HATALOVA, Antónia (703 Slovakia, guarantor), Jiri SCHWARZ (203 Czech Republic), Mirjana GOTIC (688 Serbia), Miroslav PENKA (203 Czech Republic, belonging to the institution), Mikulas HRUBISKO (703 Slovakia), Rajko KUSEC (191 Croatia), Miklos EGYED (348 Hungary), Martin GRIESSHAMMER (276 Germany), Maria PODOLAK-DAWIDZIAK (616 Poland), Andrzej HELLMANN (616 Poland), Sergiy KLYMENKO (804 Ukraine), Emilia NICULESCU-MIZII (642 Romania), Petro E. PETRIDES (276 Germany), Sebastian GROSICKI (616 Poland), Matjaz SEVER (705 Slovenia), Nathan CANTONI (756 Switzerland), Juergen THIELE (276 Germany), Dominik WOLF (40 Austria) and Heinz GISSLINGER (40 Austria).
Edition European Journal of Haematology, Hoboken, Wiley-Blackwell, 2018, 0902-4441.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30205 Hematology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 2.217
RIV identification code RIV/00216224:14110/18:00104228
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1111/ejh.13156
UT WoS 000446560100011
Keywords in English cytoreductive therapy; diagnosis; management; myeloproliferative neoplasms; polycythaemia vera; recommendations
Tags 14110212, rivok
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 10/2/2019 18:36.
Abstract
ObjectivesTo present the Central European Myeloproliferative Neoplasm Organisation (CEMPO) treatment recommendations for polycythaemia vera (PV). MethodsDuring meetings held from 2015 through 2017, CEMPO discussed PV and its treatment and recent data. ResultsPV is associated with increased risks of thrombosis/thrombo-haemorrhagic complications, fibrotic progression and leukaemic transformation. Presence of Janus kinase (JAK)-2 gene mutations is a diagnostic marker and standard diagnostic criterion. World Health Organization 2016 diagnostic criteria for PV, focusing on haemoglobin levels and bone marrow morphology, are mandatory. PV therapy aims at managing long-term risks of vascular complications and progression towards transformation to acute myeloid leukaemia and myelodysplastic syndrome. Risk stratification for thrombotic complications guides therapeutic decisions. Low-risk patients are treated first line with low-dose aspirin and phlebotomy. Cytoreduction is considered for low-risk (phlebotomy intolerance, severe/progressive symptoms, cardiovascular risk factors) and high-risk patients. Hydroxyurea is suspected of leukaemogenic potential. IFN- has demonstrated efficacy in many clinical trials; its pegylated form is best tolerated, enabling less frequent administration than standard interferon. Ropeginterferon alfa-2b has been shown to be more efficacious than hydroxyurea. JAK1/JAK2 inhibitor ruxolitinib is approved for hydroxyurea resistant/intolerant patients. ConclusionsGreater understanding of PV is serving as a platform for new therapy development and treatment response predictors.
PrintDisplayed: 31/5/2024 22:25